Checklist identification of candidates for systemic therapy in adult patients with atopic dermatitis in Germany: A multicentre study

被引:3
作者
Heratizadeh, A. [1 ,6 ]
Mempel, M. [2 ]
von Kiedrowski, R. [3 ]
Hagl, S. [4 ]
Mosch, T. [5 ]
Fritz, B. [5 ]
Werfel, T. [1 ]
机构
[1] Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany
[2] Hautarztpraxis Elmshorn, Elmshorn, Germany
[3] Co Med Study & Serv Selters GmbH CMS, Selters, Germany
[4] AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany
[5] AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany
[6] Hannover Med Sch, Dept Dermatol & Allergy, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
SEVERITY INDEX EASI; EUROPEAN TASK-FORCE; BODY-SURFACE-AREA; ECZEMA AREA; CONSENSUS REPORT; CLINICAL SIGNS; SCORAD INDEX; RELIABILITY; VALIDATION;
D O I
10.1111/jdv.19465
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background The German S2k guideline is the first to include a checklist that captures atopic dermatitis (AD) signs and symptoms as well as the lack of treatment response to identify patients eligible for systemic therapy.Objectives Identifying candidates for a start/switch of systemic therapy in adult AD patients in Germany by applying the S2k guideline's checklist.Methods In this German multicentre, cross-sectional, non-interventional study (German Clinical Trials Register number: DRKS00023296), adult patients with mild to severe AD were enrolled at dermatological outpatient clinics and offices between April and October 2021. Demographics, clinical characteristics and quality of life were collected using questionnaires during one single visit. Eligibility for a start/switch of systemic AD therapy was evaluated according to the criteria of the German S2k guideline's checklist.Results Atopic dermatitis patients (575) were included in the analysis. One hundred and sixty-four patients (28.5%) received systemic (SYS) AD therapy and 411 patients (71.5%) did not (TOP). Of the TOP therapy patients, 38.7% were eligible to start systemic AD therapy, and about half of those (49.1%), were scheduled to start systemic AD therapy. The most frequent reason deciding against a systemic therapy was the patient's wish. Although 29.3% of SYS patients were eligible for a switch according to the criteria of the German S2k guideline's checklist, the majority (81.3%) did not switch AD therapy.Conclusions This is the first study on the implementation of the German S2k guideline's checklist in everyday care of AD patients in Germany. More than one-third of the TOP patients were identified as eligible for systemic treatment. By applying the guideline's checklist criteria, another one-third of SYS patients may have benefited from a change of current systemic therapy. The use of the German S2k guideline's checklist in routine care represents an important tool to ensure effective patient care and identify inadequately treated patients.
引用
收藏
页码:157 / 166
页数:10
相关论文
共 25 条
[1]  
Augustin M., CHECKLISTE INDIKATIO
[2]   Epidemiology of atopic dermatitis in adults: Results from an international survey [J].
Barbarot, S. ;
Auziere, S. ;
Gadkari, A. ;
Girolomoni, G. ;
Puig, L. ;
Simpson, E. L. ;
Margolis, D. J. ;
de Bruin-Weller, M. ;
Eckert, L. .
ALLERGY, 2018, 73 (06) :1284-1293
[3]   The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results [J].
Basra, M. K. A. ;
Fenech, R. ;
Gatt, R. M. ;
Salek, M. S. ;
Finlay, A. Y. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (05) :997-1035
[4]   Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatogy Life Quality Index (DLQI): Further Data [J].
Basra, M. K. A. ;
Salek, M. S. ;
Camilleri, L. ;
Sturkey, R. ;
Finlay, A. Y. .
DERMATOLOGY, 2015, 230 (01) :27-33
[5]   Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis [J].
Chopra, R. ;
Vakharia, P. P. ;
Sacotte, R. ;
Patel, N. ;
Immaneni, S. ;
White, T. ;
Kantor, R. ;
Hsu, D. Y. ;
Silverberg, J. I. .
BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) :1316-1321
[6]   The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis [J].
Hanifin, JM ;
Thurston, M ;
Omoto, M ;
Cherill, R ;
Tofte, SJ ;
Graeber, M .
EXPERIMENTAL DERMATOLOGY, 2001, 10 (01) :11-18
[7]  
Haufe E, 2018, HAUTARZT, V69, P815, DOI 10.1007/s00105-018-4261-z
[8]   Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial [J].
Heratizadeh, Annice ;
Werfel, Thomas ;
Wollenberg, Andreas ;
Abraham, Susanne ;
Plank-Habibi, Sibylle ;
Schnopp, Christina ;
Sticherling, Michael ;
Apfelbacher, Christian ;
Biedermann, Tilo ;
Breuer, Kristine ;
Fell, Isabel ;
Foelster-Holst, Regina ;
Heine, Guido ;
Grimm, Jennifer ;
Hennighausen, Lars ;
Kugler, Claudia ;
Reese, Imke ;
Ring, Johannes ;
Schakel, Knut ;
Schmitt, Jochen ;
Seikowski, Kurt ;
von Stebut, Esther ;
Wagner, Nicola ;
Wassmann-Otto, Anja ;
Wienke-Graul, Ute ;
Weisshaar, Elke ;
Worm, Margitta ;
Gieler, Uwe ;
Kupfer, Joerg .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 140 (03) :845-+
[9]   Clinical validation and guidelines for the SCORAD index: Consensus report of the European task force on atopic dermatitis [J].
Kunz, B ;
Oranje, AP ;
Labreze, L ;
Stalder, JF ;
Ring, J ;
Taieb, A .
DERMATOLOGY, 1997, 195 (01) :10-19
[10]  
Langenbruch A., DDG 2019 BERL, DOI [10.1007/s00105-021-04885-3, DOI 10.1007/S00105-021-04885-3]